ACET (Adicet Bio) Ending Cash Position: $36.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACET Adicet Bio Inc ACET
34 GF Score
Price $8.29
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Ending Cash Position?

Adicet Bio ACET 34 Ending Cash Position is $36.00 Mil as of Jun. 2026. GuruFocus rates ACET with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Adicet Bio's Ending Cash Position for the quarter that ended in Jun. 2026 was $36.00 Mil.

Adicet Bio's quarterly Ending Cash Position declined from Dec. 2025 ($41.79 Mil) to Mar. 2026 ($39.11 Mil) and declined from Mar. 2026 ($39.11 Mil) to Jun. 2026 ($36.00 Mil).

Adicet Bio's annual Ending Cash Position declined from Dec. 2023 ($159.71 Mil) to Dec. 2024 ($59.40 Mil) and declined from Dec. 2024 ($59.40 Mil) to Dec. 2025 ($41.79 Mil).

Adicet Bio Ending Cash Position Related Terms

Adicet Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Ending Cash Position Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 277.69 257.66 159.71 59.40 41.79

Adicet Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.62 32.00 41.79 39.11 36.00
ACET
34GF Score
Adicet Bio Inc ACET
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Adicet Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=59.398+-17.608
=41.79

Adicet Bio's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=39.114+-3.114
=36.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $36.00 Mil mean?
Adicet Bio (ACET) has a Ending Cash Position of $36.00 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Ending Cash Position too high?
Adicet Bio's current Ending Cash Position is $36.00 Mil. Overall, Adicet Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Ending Cash Position compare to ATRA and PYPD?
Adicet Bio's Ending Cash Position of $36.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adicet Bio and its competitors. Adicet Bio's current Ending Cash Position is $36.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (ACET) has a current Ending Cash Position of $36.00 Mil. The current Ending Cash Position is $36.00 Mil. Adicet Bio's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Adicet Bio (ACET), the current Ending Cash Position is $36.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges 0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
34GF Score

Get the complete analysis for ACET

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.29
Price